EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Editas Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42+0.07 (+2.98%)
Close on Oct 19, 2026
- Market cap
- $288.69M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.35 (−35.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Editas Medicine, Inc. grew revenue 20.8% to $47.01M over the twelve months to Jun 30, 2026. Free cash flow was -$120.55M.
Revenue
$47.01M
+20.8% vs. a year earlier
Operating income
-$75.86M
TTM Q2 2026
Free cash flow
-$120.55M
TTM Q2 2026
EPS, diluted
-$0.75
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $288.69M
- P/E ratio
- –
- Price to sales
- 6.14
- Price to book
- 2.74
- Dividend yield
- –
- Free cash flow yield
- -41.76%
Fundamentals
- Revenue
- $47.01M
- Net income
- -$73.95M
- EPS, diluted
- -$0.75
- Free cash flow
- -$120.55M
- Book value per share
- $0.88
- Diluted shares
- 119M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$47.01M+20.8% YoY
Operating income
-$75.86M
Net income
-$73.95M
EPS, diluted
-$0.75
Free cash flow
-$120.55M
Reported periodTrailing twelve months